X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Sun Pharma with MYLAN INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs MYLAN (US) - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 SUN PHARMA   MYLAN
EQUITY SHARE DATA
    SUN PHARMA
Mar-16
MYLAN
Dec-14
SUN PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs1,2013,824-   
Low Rs7062,695-   
Sales per share (Unadj.) Rs117.51,309.1-  
Earnings per share (Unadj.) Rs19.6157.7-  
Cash flow per share (Unadj.) Rs23.8253.8-  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.10-  
Book value per share (Unadj.) Rs130.5650.7-  
Shares outstanding (eoy) m2,406.60378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x8.12.5 326.0%   
Avg P/E ratio x48.720.7 235.4%  
P/CF ratio (eoy) x40.112.8 311.9%  
Price / Book Value ratio x7.35.0 145.9%  
Dividend payout %5.10-   
Avg Mkt Cap Rs m2,294,8131,233,232 186.1%   
No. of employees `00014.725.0 59.0%   
Total wages/salary Rs m47,9710-   
Avg. sales/employee Rs Th19,169.819,812.6 96.8%   
Avg. wages/employee Rs Th3,253.00-   
Avg. net profit/employee Rs Th3,197.92,386.8 134.0%   
INCOME DATA
Net Sales Rs m282,697495,315 57.1%  
Other income Rs m6,170-2,887 -213.7%   
Total revenues Rs m288,867492,428 58.7%   
Gross profit Rs m83,239123,187 67.6%  
Depreciation Rs m10,13536,379 27.9%   
Interest Rs m4,76921,365 22.3%   
Profit before tax Rs m74,50562,556 119.1%   
Minority Interest Rs m-11,126-257 4,335.3%   
Prior Period Items Rs m-190-   
Extraordinary Inc (Exp) Rs m-6,8520-   
Tax Rs m9,3492,631 355.4%   
Profit after tax Rs m47,15959,669 79.0%  
Gross profit margin %29.424.9 118.4%  
Effective tax rate %12.54.2 298.4%   
Net profit margin %16.712.0 138.5%  
BALANCE SHEET DATA
Current assets Rs m308,646435,448 70.9%   
Current liabilities Rs m132,477340,433 38.9%   
Net working cap to sales %62.319.2 324.9%  
Current ratio x2.31.3 182.1%  
Inventory Days Days8378 106.3%  
Debtors Days Days88107 81.8%  
Net fixed assets Rs m133,606114,590 116.6%   
Share capital Rs m2,40717,516 13.7%   
"Free" reserves Rs m266,9090-   
Net worth Rs m314,042246,220 127.5%   
Long term debt Rs m31,167367,829 8.5%   
Total assets Rs m542,196991,753 54.7%  
Interest coverage x16.63.9 423.2%   
Debt to equity ratio x0.11.5 6.6%  
Sales to assets ratio x0.50.5 104.4%   
Return on assets %9.68.2 117.2%  
Return on equity %15.024.2 62.0%  
Return on capital %17.813.6 130.3%  
Exports to sales %14.00-   
Imports to sales %3.10-   
Net fx Rs m20,5880-   
CASH FLOW
From Operations Rs m67,69465,110 104.0%  
From Investments Rs m-44,549-51,347 86.8%  
From Financial Activity Rs m-19,243-17,156 112.2%  
Net Cashflow Rs m3,902-3,394 -115.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 64.16 Rs / USD

Compare SUN PHARMA With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare SUN PHARMA With: J.B.CHEMICALS  ELDER PHARMA  BIOCON LTD  GSK PHARMA  NOVARTIS  



Today's Market

Vishal Sikka's Infosys Exit, White House Shake up & Cues to Watch Out Today(Pre-Open)

Indian share markets ended lower on Friday but gained during the overall week. At the closing bell on Friday, BSE Sensex closed lower by 271 points and the NSE Nifty finished down 67 points.

Related Views On News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Aug 18, 2017 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA 8-QTR ANALYSIS

COMPARE SUN PHARMA WITH

MARKET STATS